Objective: To study the effect of arsenic trioxide (As2O3) on the metabolism of leukemia K562 cells. Methods: Firstly, the effect of As2O3 on the viability of K562 cells was detected by CCK-8 assay. Then, the metabolites in the cells after As2O3 incubation were identified by ultra-high performance liquid chromatography-mass spectrometry, and the differential metabolites were screened and KEGG enrichment analysis was performed. Results: CCK-8 results showed that As2O3 could decrease the survival rate of K562 cells in a dose-dependent manner. The results of non-targeted metabolomics showed that As2O3 could lead to significant changes in the content of multiple metabolites in K562 cells. KEGG enrichment analysis showed that the differential metabolites were mainly enriched in glutathione metabolism, ferroptosis, linoleic acid metabolism, taurine metabolism, choline metabolism in cancer, purine metabolism and other pathways. Conclusion: As2O3 can significantly decrease the survival rate of K562 cells, which may be related to the influence of various metabolic homeostasis of cells, resulting in the inhibition of cell proliferation and the induction of apoptosis. In addition, whether As2O3 can induce ferroptosis in K562 cells is still worthy of further study.
[1] Zhang JZ, Zhang M, Liang Y, et al. Down regulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells[J]. Hematology, 2022, 27(1): 43-52.
[2] Bispoj AB, Pinheirop S, Kobetze K. Epidemiology and etiology of leukemia and lymphoma[J]. Cold Spring Harb Perspect Med, 2020, 10(6): a034819.
[3] Claudiani S, Apperley JF. The argument for using imatinib in CML[J]. Hematology Am Soc Hematol Educ Program, 2018, 2018(1): 161-167.
[4] Lindauer M, Hochhaus A. Dasatinib[J]. Recent Results Cancer Res, 2018, 212: 29-68.
[5] Ostendorf BN, Le Coutre P, Kim TD, et al. Nilotinib[J]. Recent Results Cancer Res, 2014, 201: 67-80.
[6] Yousefnia S. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias[J]. Cell Biol Int, 2021, 45(6): 1148-1157.
[7] Wang Y, Yang J, Li J, et al. Effect of arsenic trioxide on K562 cell proliferation and its mechanism[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2017, 25(1): 90-93.
[8] Xu XP, Xu XW, Yi K, et al. Arsenic trioxide induced leukemic cell apoptosis relative to NF-kappaB activation[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2005, 13(5): 764-768.
[9] Shim MJ, Kim HJ, Yang SJ, et al. Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase[J]. J Biochem Mol Biol, 2002, 35(4): 377-383.
[10] Lang WJ, Zhu JY, Chen FY, et al. EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells[J]. Exp Cell Res, 2019, 374(1): 140-151.
[11] Chen ZQ, Zhang HN, Yang LN, et al. Construction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901[J]. Acta BiochimBiophys Sin, 2016, 48(5): 474-481.
[12] Georgiou-Siafiss K, Samiotakim K, Demopoulosv J, et al. Glutathione-hemin/hematin adduct formation to disintegrate cytotoxic oxidant hemin/hematin in human K562 cells and red blood cells' hemolysates: impact of glutathione on the hemolytic disorders and homeostasis[J]. Antioxidants, 2022, 11(10): 1959.
[13] Singh P, Yadav R, Verma M, et al. Antileukemic activity of hsa-miR-203a-5p by limiting glutathione metabolism in imatinib-resistant K562 cells[J]. Curr Issues Mol Biol, 2022, 44(12): 6428-6438.
[14] Kalininae V, Saprina N, Solomkav S, et al. Role of the antioxidant system and redox-dependent regulation of transcription factors bcl-2 and p53 in forming resistance of human K562 erythroleukemia cells to doxorubicin[J]. VoprOnkol, 2001, 47(5): 595-600.
[15] Huangc H, Leey C, Chiouj T, et al. Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells[J]. Toxicol Appl Pharmacol, 2020, 397: 115013.
[16] Chen Z, Jiang JY, Fu N, et al. Targetting ferroptosis for blood cell-related diseases[J]. J Drug Target, 2022, 30(3): 244-258.
[17] Chen X, Kang R, Kroemer G, et al. Broadening horizons: the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5): 280-296.
[18] TAng SS, Shen YM, Wei XY, et al. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer[J]. Cell Death Dis, 2022, 13(9): 826.
[19] Wang LY, Liu SG, Gao C, et al. Arsenic trioxide-induced cardiotoxicity triggers ferroptosis in cardiomyoblast cells[J]. Hum Exp Toxicol, 2022, 41: 9603271211064537.
[20] Feng CC, Wu Y, Chen YT, et al. Arsenic trioxide increases apoptosis of SK-N-BE (2) cells partially by inducing GPX4-mediated ferroptosis[J]. Mol Biol Rep, 2022, 49(7): 6573-6580.
[21] Phoonm C, Desbordes C, Howe J, et al. Linoleic and linolelaidic acids differentially influence proliferation and apoptosis of MOLT-4 leukaemia cells[J]. Cell Biol Int, 2001, 25(8): 777-784.
[22] Qiu TM, Pei P, Yao XF, et al. Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway[J]. Cell Death Dis, 2018, 9(10): 946.
[23] Li WW, Wu GF, Yang XJ, et al. Taurine prevents AFB1-induced renal injury by inhibiting oxidative stress and apoptosis[J]. Adv Exp Med Biol, 2022, 1370: 435-444.
[24] Wu PG, Shi XX, Luo MX, et al. Taurine inhibits neuron apoptosis in hippocampus of diabetic rats and high glucose exposed HT-22 cells via the NGF-Akt/Bad pathway[J]. Amino Acids, 2020, 52(1): 87-102.
[25] Islambulchilar M, Asvadi I, Sanaat Z, et al. Taurine attenuates chemotherapy-induced nausea and vomiting in acute lymphoblastic leukemia[J]. Amino Acids, 2015, 47(1): 101-109.
[26] Zhou X, Zheng MH, Wang QE, et al. Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients[J]. Int J Hematol, 2020, 111(6): 761-770.
[27] Sonkar K, Ayyappan V, Tressler CM, et al. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer[J]. NMR Biomed, 2019, 32(10): e4112.
[28] Dutta N, Deb I, Sarzynska J, et al. Inosine and its methyl derivatives: occurrence, biogenesis, and function in RNA[J]. Prog Biophys Mol Biol, 2022, 169/170: 21-52.
[29] Srinivasan S, Torresa G, Ribasde Pouplana L. Inosine in biology and disease[J]. Genes, 2021, 12(4): 600.
